We showed that vaccination with a heterologous mRNA COVID-19 booster did not report a higher frequency of adverse reactions compared to those vaccinated with a homologous booster, and that booster doses had a similar safety profile as compared to the primary doses with the same vaccine type. We also characterized the re-infection of SARS-CoV-2 and the circulation of the viral lineages. We have participated in three large phase II and III trials on COVID-19 vaccines for general population (Ad26.COV2.S and COVID-19 HIPRA) and in pregnancy (BNT162b2). We have been actively involved in an EU consortium to monitor and assess brand-specific COVID-19 vaccine effectiveness (COVIDRIVE) and more recently in a world consortium to monitor vaccine safety (VAC4EU). Finally, we have also contributed to define the prognostic role of oral contraceptives and menopause in women with Multiple Sclerosis (MS) and continued to establish a research line on vaccination in MS patients, leading an EU consensus.

Group Leader
Susana Otero Romero

Principal Investigator (PI)
Susana Otero Romero, Magda Campins Martí, Xavier Martínez Gómez, Lluís Armadans Gil

José María Sanchez García, Jose Ángel Rodrigo Pendas, Oleguer Parés Badell, Blanca Borrás Bermejo, Ricardo Gabriel Zules Oña, César Llorente Parrado, Irene Torrecilla Martínez, Mar Fornaguera Padrós, Arnau Peñalver Piñol, Martí Vivet Escalé, Gabriela Tejada Panduro, David Guananga Alvarez, Paula Fernandez Torres

Nursing and Technical Staff
Laia Pinós Tella, Elisa Navarro Royo, Cristian Quintana Alonso, Agustín Gayubas Jurado, Marta Rodríguez Torrecillas, Carmen Ferrer Barbera, Eva del Amo Moran, Íngrid Carbonés Fargas, Constanza Olivares Castillo










Borras-Bermejo B, Pinana M, Andres C, Zules R, Gonzalez-Sanchez A, Esperalba J, Pares-Badell O, Garcia-Cehic D, Rando A, Campos C, Codina MG, Martin MC, Castillo C, Garcia-Comunas K, Vasquez-Mercado R, Martins-Martins R, Colomer-Castell S, Pumarola T, Campins M, Quer J, Anton A
Characteristics of 24 SARS-CoV-2-Sequenced Reinfection Cases in a Tertiary Hospital in Spain
Front Microbiol. 2022; 13: 876409
DOI: doi: 10.3389/fmicb.2022.876409
IF: 6.064

Pares-Badell O, Zules-Ona R, Armadans L, Pinos L, Borras-Bermejo B, Otero S, Rodrigo-Pendas JA, Vivet-Escale M, Cossio-Gil Y, Agusti A, Aguilera C, Campins M, Martinez-Gomez X
Reactogenicity to the mRNA-1273 booster according to previous mRNA COVID-19 vaccination
Vaccines (Basel). 2022 Jul 29;10(8). pii: vaccines10081217
DOI: doi: 10.3390/vaccines10081217
IF: 4.961

Otero-Romero S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, Galan I, Cobo-Calvo A, Rio J, Arrambide G, Vidal-Jordana A, Castillo J, Rodriguez-Acevedo B, Comabella M, Rodriguez M, Tur C, Auger C, Rovira A, Sastre-Garriga J, Montalban X, Tintore M
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis
Mult Scler. 2022 May;28(6):950-957
DOI: doi: 10.1177/13524585211053001
IF: 5.855

Authors Andres C, Pinana M, Borras-Bermejo B, Gonzalez-Sanchez A, Garcia-Cehic D, Esperalba J, Rando A, Zules-Ona RG, Campos C, Codina MG, Blanco-Grau A, Colomer-Castell S, Martin MC, Castillo C, Garcia-Comunas K, Vasquez-Mercado R, Martins-Martins R, Campins-Marti M, Pumarola T, Quer J, Anton A
A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain)
Emerg Microbes Infect. 2022 Dec;11(1):172-181
DOI: doi: 10.1080/22221751.2021.2011617
IF: 6,212

Otero-Romero S, Midaglia L, Carbonell-Mirabent P, Zuluaga M, Galan I, Rio J, Arrambide G, Rodriguez-Barranco M, Vidal-Jordana A, Castillo J, Rodriguez-Acevedo B, Zabalza A, Nos C, Comabella Lopez M, Mulero P, Auger C, Sastre-Garriga J, Perez-Hoyos S, Rovira A, Montalban X, Tintore M
Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset
Eur J Neurol. 2022 Apr;29(4):1075-1081
DOI: doi: 10.1111/ene.14782
IF: 6.288

Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple (PI19/01606)
Principal Investigator: Susana Otero Romero
Agency: Instituto de Salud Carlos III
Funding: 105,270 €
Period: 2020-2022

Genomics study of COVID-19 vaccine-induced Guillain-Barre syndrome, Autoimmune thrombotic thrombocytopenia/Thrombosis with thrompocytopenia and myocarditis/pericarditis
Principal Investigator: Xavier Martínez Gómez
Agency: Vaccine monitoring Collaboration for Europe (VAC4EU)
Funding: 17,500 USD
Period: 2022-2024 (estimated)

Brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe (COVIDRIVE)
Principal Investigator: Susana Otero Romero / Andrés Antón Pagarolas
Agency: Public-private partnership (membres FISABIO, P95, IABS-EU, THL, AstraZeneca, CureVac, Janssen, Sanofi-Pasteur, GSK, Bavarian Nordic, Moderna, Novavax and Valneva)
Funding: 127,000 €/year (estimated)
Period: 2021-2023

A phase IIB, double-blind, randomised, active-controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fully vaccinated against covid-19 followed by an extension period to study a fourth dose administration of PHH-1V
Principal Investigator: Susana Otero Romero
Funding: -
Period: 2021-2023

Efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 (ENSEMBLE 2)
Principal Investigator: Susana Otero Romero
Agency: Janssen Vaccines & Prevention
Funding: -
Period: 2020-2023